Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada

Por Attard, C.L., Maroun, J.A., Alloul, K., Grima, D.T., Bernard, L.M.
Publicado em 2010

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Por Grima, D. T., Papaioannou, A., Thompson, M. F., Pasquale, M. K., Adachi, J. D.
Publicado no Osteoporos Int (2007)